Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Willem J. A. Witlox*, Antoinette D. I. van Asselt, Robert Wolff, Nigel Armstrong, Gill Worthy, Annette Chalker, Titas Buksnys, Lisa Stirk, Jos Kleijnen, Manuela A. Joore, Sabine E. Grimm

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)317-324
Number of pages8
JournalPharmacoeconomics
Volume38
Issue number4
Early online date9 Dec 2019
DOIs
Publication statusPublished - Apr 2020

Cite this